Recent Theranostic Publications

The ICPO Foundation is excited to introduce a new resource for theranostic centers, a detailed list of recent publications in the field. This collection is designed to serve as a valuable reference for theranostic centers worldwide, offering insights into the latest research, innovations, and clinical practices. Stay updated with cutting-edge developments in theranostics and enhance your center's expertise with these essential references.

 

1. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.

Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M, Graham MM, Grimm J, Herrmann K, Kostakoglu L, Lewis JS, Mankoff DA, Peterson TE, Schelbert H, Schöder H, Siegel BA, Strauss HW.
J Nucl Med. 2020 Dec;61(Suppl 2):263S-272S. doi: 10.2967/jnumed.120.254532.

https://pubmed.ncbi.nlm.nih.gov/33293447/

 

2. Radiotheranostics: a roadmap for future development.

Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, Gambhir SS, Hricak H, Weissleder R.
Lancet Oncol. 2020 Mar;21(3):e146 e156. doi: 10.1016/S1470-2045(19)30821-6..

https://pubmed.ncbi.nlm.nih.gov/32135118/

 

3. Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright.

Czernin J, Calais J.
J Nucl Med Technol. 2020 Jun;48(Suppl 1):82S-83S..

https://pubmed.ncbi.nlm.nih.gov/32605963/

 

4. Present and future of target therapies and theranostics: refining traditions and exploring new frontiers-highlights from annals of Nuclear Medicine 2021.

Pini C, Gelardi F, Sollini M.
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3613-3621. doi: 10.1007/s00259-022-05921-7

https://pubmed.ncbi.nlm.nih.gov/35870007/

 

5. Next generation radiotheranostics promoting precision medicine.

Pomykala KL, Hadaschik BA, Sartor O, Gillessen S, Sweeney CJ, Maughan T, Hofman MS, Herrmann K.
Ann Oncol. 2023 Jun;34(6):507-519. doi: 10.1016/j.annonc.2023.03.001. Epub 2023 Mar 15.

https://pubmed.ncbi.nlm.nih.gov/36924989/

 

6. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators.
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23..

https://pubmed.ncbi.nlm.nih.gov/34161051/

 

7. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.

Arbuznikova D, Klotsotyra A, Uhlmann L, Domogalla LC, Steinacker N, Mix M, Niedermann G, Spohn SKB, Freitag MT, Grosu AL, Meyer PT, Gratzke C, Eder M, Zamboglou C, Eder AC.
Theranostics. 2024 Apr 8;14(6):2560-2572. doi: 10.7150/thno.93249. eCollection 2024.

https://pubmed.ncbi.nlm.nih.gov/38646643/

 

8. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).

Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K.
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29.

https://pubmed.ncbi.nlm.nih.gov/37246997/

 

9. Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose.

Lawhn-Heath C, Hope TA, Martinez J, Fung EK, Shin J, Seo Y, Flavell RR.
Lancet Oncol. 2022 Feb;23(2):e75-e87. doi: 10.1016/S1470-2045(21)00657-4.

https://pubmed.ncbi.nlm.nih.gov/35114134/

 

10. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy.

Graves SA, Hobbs RF.
Semin Radiat Oncol. 2021 Jan;31(1):37-44. doi: 10.1016/j.semradonc.2020.07.008..

https://pubmed.ncbi.nlm.nih.gov/33246635/

 

11. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics center.

Herrmann K, Giovanella L, Santos A, Gear J, Kiratli PO, Kurth J, Denis-Bacelar AM, Hustinx R, Patt M, Wahl RL, Paez D, Giammarile F, Jadvar H, Pandit-Taskar N, Ghesani M, Kunikowska J.
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2300-2309. doi: 10.1007/s00259-022-05785-x. Epub 2022 Apr 11.

https://pubmed.ncbi.nlm.nih.gov/35403861/

 

12. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.

Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR.
J Nucl Med. 2022 Mar;63(3):415-423. doi: 10.2967/jnumed.120.259192. Epub 2021 Jun 24.

https://pubmed.ncbi.nlm.nih.gov/34168013/

 

13. Impact of theranostics tumor board on clinical management of patients referred for radiopharmaceutical therapy

Vikas Prasad, Hyun Kim, Nikolaos Trikalinos, Melissa Reimers, Hiram Gay, Joel Picus, Russell Pachynski, Jeff Michalski, Farrokh Dehdashti and Richard Wahl
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 242589.

Impact of theranostics tumor board on clinical management of patients referred for radiopharmaceutical therapy | Journal of Nuclear Medicine (snmjournals.org)

 

14. Clinical relevance of post-therapy SPECT/CT in prostate cancer patients treated with Lutetium Lu 177 vipivotide tetraxetan

Vikas Prasad, Hyun Kim, Jeff Michalski, Richard Laforest, Joel Picus, Russell Pachynski, Hiram Gay, Melissa Reimers, Richard Wahl and Farrokh Dehdashti
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 242599;.

Clinical relevance of post-therapy SPECT/CT in prostate cancer patients treated with Lutetium Lu 177 vipivotide tetraxetan | Journal of Nuclear Medicine (snmjournals.org)

 

15. Recent advances and impending challenges for the radiopharmaceutical sciences in oncology

Prof Suzanne E Lapi PhD a *, Prof Peter J H Scott PhD b *, Prof Andrew M Scott MD c d e f *, Prof Albert D Windhorst PhD g h *, Prof Brian M Zeglis PhD i j k *, Prof May Abdel-Wahab MD m, Prof Richard P Baum MD PhD q, Prof John M Buatti MD r, Prof Francesco Giammarile MD PhD n s, Ana P Kiess MD PhD t, Prof Amirreza Jalilian PhD p, Peter Knoll PhD o, Aruna Korde PhD p, Prof Jolanta Kunikowska MD PhD u, Prof Sze Ting Lee MBBS c d e f, Diana Paez MD n, Jean-Luc Urbain MD v, Jingjing Zhang MD PhD w x, Prof Jason S Lewis PhD j k l

Recent advances and impending challenges for the radiopharmaceutical sciences in oncology - ScienceDirect

 

16. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients.

Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C.
Theranostics. 2020 Jul 23;10(20):9364-9377. doi: 10.7150/thno.48107. eCollection 2020.PMID: 32802197.

https://pubmed.ncbi.nlm.nih.gov/32802197/

 

17. Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers.

Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, Tripathi M, ArunRaj ST, Sarswat S, Bal C.
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1915-1931. doi: 10.1007/s00259-020-05132-y. Epub 2020 Nov 26.PMID: 33244617.

https://pubmed.ncbi.nlm.nih.gov/33244617/

 

18. Production and regulatory issues for theranostics.

Giammarile F, Paez D, Zimmermann R, Cutler CS, Jalilian A, Korde A, Knoll P, Ayati N, Lewis JS, Lapi SE, Delgado Bolton RC, Kunikowska J, Estrada Lobato E, Urbain JL, Holmberg O, Abdel-Wahab M, Scott AM.
Lancet Oncol. 2024 Jun;25(6):e260-e269. doi: 10.1016/S1470-2045(24)00041-X.PMID: 38821100.

https://pubmed.ncbi.nlm.nih.gov/38821100/

 

19. Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.

Lapi SE, Scott PJH, Scott AM, Windhorst AD, Zeglis BM, Abdel-Wahab M, Baum RP, Buatti JM, Giammarile F, Kiess AP, Jalilian A, Knoll P, Korde A, Kunikowska J, Lee ST, Paez D, Urbain JL, Zhang J, Lewis JS.
Lancet Oncol. 2024 Jun;25(6):e236-e249. doi: 10.1016/S1470-2045(24)00030-5.PMID: 38821098.

https://pubmed.ncbi.nlm.nih.gov/38821098/

 

20. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics.

Scott AM, Zeglis BM, Lapi SE, Scott PJH, Windhorst AD, Abdel-Wahab M, Giammarile F, Piaez D, Jalilian A, Knoll P, Korde A, Vichare S, Ayati N, Lee ST, Lyashchenko SK, Zhang J, Urbain JL, Lewis JS.
Lancet Oncol. 2024 Jun;25(6):e250-e259. doi: 10.1016/S1470-2045(24)00037-8.PMID: 38821099.

https://pubmed.ncbi.nlm.nih.gov/38821099/

 

21. First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Hofman MS, Tran B, Feldman DR, Pokorska-Bocci A, Pichereau S, Wessen J, Haskali MB, Sparks RB, Vlasyuk O, Galetic I.

J Nucl Med. 2024 Feb 22;65(5):740-3. doi: 10.2967/jnumed.123.267175. Online ahead of print.PMID: 38388517

https://pubmed.ncbi.nlm.nih.gov/38388517/

 

22. A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac)-labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).

Michael J. Morris, Jeffrey Y.C. Wong, Luke Nordquist, Russell Zelig Szmulewitz, Neeraj Agarwal, Edward F. Attiyeh, Steven I Max, Chaitanya R. Divgi, Daniel Patricia, Yu Cao, Xiang Li, Alex Yu, Karen Urtishak, Josh David Lauring, and Oliver Sartor

Journal of Clinical Oncology Volume 42, Number 16_suppl

https://doi.org/10.1200/JCO.2024.42.16_suppl.5010

 

23. Actinium-225 targeted alpha particle therapy for prostate cancer.

Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR.

Theranostics. 2024 May 11;14(7):2969-2992. doi: 10.7150/thno.96403. eCollection 2024.PMID: 38773983

https://pubmed.ncbi.nlm.nih.gov/38773983/

 

24. Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides.

Baum RP, Novruzov E, Zhao T, Greifenstein L, Jakobsson V, Perrone E, Mishra A, Eismant A, Ghai K, Klein O, Jaeschke B, Benz-Zils D, Cardinale J, Mori Y, Giesel FL, Zhang J.

Semin Nucl Med. 2024 Jul;54(4):537-556. doi: 10.1053/j.semnuclmed.2024.05.010. Epub 2024 Jul 16.PMID: 39019653

https://pubmed.ncbi.nlm.nih.gov/39019653/

 

25. Guiding principles on the education and practice of theranostics.

Pascual TNB, Paez D, Iagaru A, Gnanasegaran G, Lee ST, Sathekge M, Buatti JM, Giammarile F, Al-Ibraheem A, Pardo MA, Baum RP, De Bari B, Ben-Haim S, Blay JY, Brink A, Estrada-Lobato E, Fanti S, Golubic AT, Hatazawa J, Israel O, Kiess A, Knoll P, Louw L, Mariani G, Mirzaei S, Orellana P, Prior JO, Urbain JL, Vichare S, Vinjamuri S, Virgolini I, Scott AM.

Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2320-2331. doi: 10.1007/s00259-024-06657-2. Epub 2024 Mar 8.PMID: 38453729 

https://pubmed.ncbi.nlm.nih.gov/38453729/

 

26. Theranostics and artificial intelligence: new frontiers in personalized medicine.

Belge Bilgin G, Bilgin C, Burkett BJ, Orme JJ, Childs DS, Thorpe MP, Halfdanarson TR, Johnson GB, Kendi AT, Sartor O.

Theranostics. 2024 Mar 25;14(6):2367-2378. doi: 10.7150/thno.94788. eCollection 2024.PMID: 38646652

https://pubmed.ncbi.nlm.nih.gov/38646652/

 

27. Immune Response to Molecular Radiotherapy with 177Lu-DOTATOC: Predictive Value of Blood Cell Counts for Therapy Outcome.

Kluge A, Baum RP, Bitterlich N, Kulkarni HR, Schorr-Neufing U, van Echteld CJA.

Cancer Biother Radiopharm. 2024 Sep;39(7):541-550. doi: 10.1089/cbr.2024.0031. Epub 2024 Jun 21.PMID: 38905126

https://pubmed.ncbi.nlm.nih.gov/38905126/

 

28. Theranostics: Timing is Everything.

Turner JH. Cancer Biother

Radiopharm. 2024 Nov;39(9):611-618. doi: 10.1089/cbr.2024.0088. Epub 2024 May 17.PMID: 38757676

https://pubmed.ncbi.nlm.nih.gov/38757676/

 

29. Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.

Prasad V, Koumarianou A, Denecke T, Sundin A, Deroose CM, Pavel M, Christ E, Lamarca A, Caplin M, Castaño JP, Dromain C, Falconi M, Grozinsky-Glasberg S, Hofland J, Knigge UP, Kos-Kudla B, Krishna BA, Reed NS, Scarpa A, Srirajaskanthan R, Toumpanakis C, Kjaer A, Hicks RJ, Ambrosini V.J

Neuroendocrinol. 2024 Dec 9:e13479. doi: 10.1111/jne.13479. Online ahead of print.PMID: 39653582

https://pubmed.ncbi.nlm.nih.gov/39653582/

 

30. Total-Body PET/CT: Pros and Cons

Rodney J. Hicks AM, MBBS (Hons), MD, FRACP, FAAHMS, FICIS * †, Robert E. Ware MBBS, FCP, FAANMS *, Jason Callahan BAppSci (MedRad), PhD The Melbourne Theranostic Innovation Centre, North Melbourne, Victoria 3051, Australia St Vincent's Hospital, Department of Medicine, The University of Melbourne, Fitzroy, Victoria 3065, Australia

https://www.sciencedirect.com/science/article/pii/S0001299824000655

 

31. The Lancet Commission on prostate cancer: planning for the surge in cases

Prof Nicholas Jamesa,b nick.james@icr.ac.uk ∙ Ian Tannock, MDc ∙ James N'Dow, FRCSd ∙ Felix Feng, MDe ∙ Prof Silke Gillessenf ∙ Syed Adnan Ali, PhDg,h ∙ Blanca Trujillo, PhDi ∙ Bissan Al-Lazikani, PhDj ∙ Gerhardt Attard, PhDi ∙ Freddie Bray, PhDk ∙ Eva Compérat, PhDl,m ∙ Prof Ros Eeles, PhDa,b ∙ Omolara Fatiregunn ∙ Emily Grist, PhDi ∙ Susan Halabi, PhDo ∙ Áine Haranp ∙ Daniel Herchenhornq ∙ Michael Hofmanr ∙ Mohamed Jalloh, MDs ∙ Stacy Loeb, MDt,u ∙ Archie MacNairi ∙ Brandon Mahal, MDv ∙ Larissa Mendes, MDi ∙ Masood Moghul, FRCSa,b ∙ Caroline Moore, MDi ∙ Alicia Morgans, MDw ∙ Michael Morris, MDx ∙ Declan Murphy, FRCS Urolr ∙ Vedang Murthy, MDy ∙ Paul Nguyen, MDz ∙ Anwar Padhani, FRCRaa ∙ Charles Parkeri ∙ Hannah Rush, MDi ∙ Mark Sculpher, PhDab ∙ Howard Soule, PhDac ∙ Matthew R Sydes, MSci ∙ Derya Tilki, MDad,ae ∙ Nina Tunariu, FRCRa,b ∙ Paul Villantiaf ∙ Li-Ping Xie, MD

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2900651-2/fulltext

 

32. Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study

Manuel Weber a †, Wolfgang P. Fendler a †, Aravind S. Ravi Kumar b c d, Jeremie Calais e, Johannes Czernin e, Harun Ilhan f, Fred Saad g, Alexander Kretschmer h i, Turkay Hekimsoy j, Sabine D. Brookman-May h i, Suneel D. Mundle k, Eric J. Small l, Matthew R. Smith m, Paola M. Perez l, Thomas A. Hope l, Ken Herrmann a, Michael S. Hofman b c d, Matthias Eiber j ‡, Boris A. Hadaschik n

https://doi.org/10.1016/j.eururo.2024.01.019

 

33. Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial

Michael Hofmana,b,† Michael.Hofman@petermac.org ∙ Veeru Kasivisvanathanc,d,† veeru.kasi@ucl.ac.uk ∙ Emma Linkb,e ∙ James Buteaua,b ∙ Matthew J. Robertsf ∙ Roslyn J. Francisg,‡ ∙ Colin Tangh ∙ Ian Velai ∙ Paul Thomasj,k ∙ Natalie Rutherfordl ∙ Jarad M. Martinm ∙ Mark Frydenbergn ∙ Ramdave Shakhero ∙ Lih-Ming Wongp ∙ Kim Taubmanq ∙ Sze Ting Leer ∙ Edward Hsiaos ∙ Paul Roachs ∙ Michelle Nottaget,u ∙ Ian Kirkwoodv,w ∙ Dickon Haynex ∙ Amir Iravania,b ∙ Scott Williamsb,y,z ∙ Jonathan O’Brienc ∙ Nathan Lawrentschukb,aa ∙ Declan G. Murphyb,c

https://euoncology.europeanurology.com/article/S2588-9311%2824%2900251-7/fulltext

 

34. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Silke Gillessen 1 2, Fabio Turco 1, Ian D. Davis 3 4, Jason A. Efstathiou 5, Karim Fizazi 6, Nicholas D. James 7, Neal Shore 8, Eric Small 9, Matthew Smith 10, Christopher J. Sweeney 11, Bertrand Tombal 12, Thomas Zilli 1 2, Neeraj Agarwal 13, Emmanuel S. Antonarakis 14, Ana Aparicio 15, Andrew J. Armstrong 16, Diogo Assed Bastos 17, Gerhardt Attard 18, Karol Axcrona 19 20, Mouna Ayadi 21…Aurelius Omlin 126

https://www.sciencedirect.com/science/article/pii/S0302283824026101

 

35. Advances and challenges in precision imaging

Prof Hedvig Hricak MD PhD a, Prof Marius E Mayerhoefer MD PhD b c, Prof Ken Herrmann MD d e, Prof Jason S Lewis PhD a f, Prof Martin G Pomper MD PhD g, Prof Christopher P Hess MD PhD h, Prof Katrine Riklund MD PhD i, Prof Andrew M Scott MD j k l m, Prof Ralph Weissleder MD PhD n o

https://www.sciencedirect.com/science/article/pii/S1470204524003954

 

36. Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy

Adriana Amerein, Christoph Maurer, Malte Kircher, Alexander Gäble, Anne Krebold, Andreas Rinscheid, Oliver Viering, Christian H. Pfob, Ralph A. Bundschuh, Lars Behrens, Arthur JAT Braat, Ansgar Berlis and Constantin Lapa.

Journal of Nuclear Medicine December 2024, 65 (12) 1911-1916; DOI:

https://doi.org/10.2967/jnumed.124.268217

 

37. Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach.

Oron-Herman, M., Kirmayer, D., Lupp, A. et al.

Sci Rep 13, 20857 (2023).

https://doi.org/10.1038/s41598-023-47877-0

 

38. Dotatate PET/CT and 225Ac-Dotatate Therapyfor Somatostatin Receptor–expressing MetastaticBreast Cancer

Gary A. Ulaner, MD, PhD • Louis A. VanderMolen, MD • Gary Li, PhD • Denis Ferreira, MDFrom the Department of Molecular Imaging and Therapy, Hoag Family Cancer Institute, 16105 Sand Canyon Ave, Irvine, CA 92618 (G.A.U.); Department of Radiologyand Translational Genomics (G.A.U.) and Department of Medicine (L.A.V.), University of Southern California, Los Angeles, Calif; and RayzeBio, San Diego, CA (G.L.,D.F.). Received December 19, 2023; revision requested January 26, 2024; final revision received April 4; accepted April 16. Address correspondence to G.A.U. (email:gary.ulaner@hoag.org).G.A.U. is supported in part by the Hoag Hospital Foundation, James & Pamela Muzzy Endowed Chair, and RayzeBio.Conflicts of interest are listed at the end of this article.See also the editorial by Lin and Choyke in this issue.Radiology 2024; 312(1):e233408

https://doi.org/10.1148/radiol.233408